Back to Search Start Over

Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicelter study

Authors :
Martire, B
Rondelli, R
Soresina, A
Pignata, C
Broccoletti, T
Finocchi, A
Rossi, P
Gattorno, M
Rabusin, M
Azzari, C
Dellepiane, Rm
Pietrogrande, Mc
Trizzino, A
Di Bartolomeo, P
Martino, Silvana
Carpino, L
Cossu, F
Locatelli, F
Maccario, R
Pierani, P
Putti, Mc
Stabile, A
Notarangelo, Ld
Ugazio, Ag
Plebani, A
De Mattia, D
Ipinet
Martire, B
Rondelli, R
Soresina, A
Pignata, Claudio
Broccoletti, Teresa
Finocchi, A
Rossi, P
Gattorno, M
Rabusin, M
Azzari, C
Dellepiane, R. M.
Pietrogrande, M. C.
Trizzino, A
DI BARTOLOMEO, P
Martino, S
Carpino, L
Cossu, F
Locatelli, F
Maccario, R
Pievani, P
Putti, M. C.
Stabile, A
Notarangelo, L. D.
Ugazio, A. G.
Plebani, A
DE MATTIA, D.
Publication Year :
2008
Publisher :
Elsevier Science Incorporated / NY Journals:Madison Square Station, PO Box 882:New York, NY 10159:(212)633-3730, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: (212)633-3680, 2008.

Abstract

A retrospective clinical and immunological survey was conducted in 60 patients with Chronic Granulomatous Disease. A prospective controlled non-randomized study of the efficacy of long-term IFNgamma treatment was carried out. The mean age at the time of diagnosis was 4.4 years; mean duration of follow-up was 10.4 years. Lung and skin infections were the most frequent manifestations both prior to diagnosis and during follow-up. Aspergillus species was the first cause of infection and of death in our cohort. The mortality rate was 13%. Long term prophylaxis with IFNgamma did not significantly change the rate of total infection per patient-year compared to controls (p=0.07). Our data provide clear evidence that protocols of continuing intensive surveillance and monitoring of compliance with anti-infective regimens may significantly improve the quality of life and long-term survival in patients with CGD. No evidence justifying long-term prophylaxis with IFNgamma was obtained.

Subjects

Subjects :
Male
absence of side effects
Granulomatous Disease, Chronic
cause of death
Chronic granulomatous disease
Anti-Infective Agents
amphotericin B
cotrimoxazole
fluconazole
gamma interferon
itraconazole
voriconazole
adolescent
adult
article
brain abscess
child
chronic granulomatous disease
clinical feature
clinical trial
cohort analysis
conjunctivitis
controlled clinical trial
controlled study
dermatitis
disease course
drug efficacy
drug withdrawal
enteritis
enterocolitis
fatigue
female
fever
follow up
function test
granulocyte function
headache
human
incidence
liver abscess
long term care
lung abscess
lymphadenitis
male
multicenter study
myalgia
osteomyelitis
otitis
pneumonia
priority journal
prophylaxis
prospective study
rash
septicemia
single drug dose
sinusitis
skin abscess
survival rate
treatment duration
Antifungal Agents
Antiviral Agents
Bacterial Infections
Child
Child, Preschool
Cohort Studies
Female
Follow-Up Studies
Humans
Infant
Interferon Type II
Italy
Itraconazole
Kaplan-Meiers Estimate
Retrospective Studies
Treatment Outcome
Trimethoprim-Sulfamethoxazole Combination
Immunopathology
Chronic
Interferon gamma (IFNγ)
Cohort
clinica features
Cohort study
medicine.medical_specialty
Cotrimoxazole (CTX)
Immunology
Interferon-gamma
Settore MED/38 - Pediatria Generale e Specialistica
Follow up
Itraconazole (ITRA)
medicine.disease
Kaplan-Meier Estimate
Skin infection
Immunology and Allergy
Mortality rate
Granulomatous Disease
medicine.drug
Chronic Granulomatous Disease (CGD)
Infections
Internal medicine
Trimethoprim, Sulfamethoxazole Drug Combination
medicine
Preschool
business.industry
Retrospective cohort study
Surgery
business

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....239c1ff17b1a9a010544e3a64ce9955a